A 6-month-old female infant from Delhi presents with a 3-day history of cough, fever (38.5°C), and rapid breathing (respiratory rate 52/min). On auscultation, there are crackles in the right lower lobe. Chest X-ray shows right lower lobe consolidation. Blood culture grows a gram-negative coccobacillus that requires both X and V factors for growth on chocolate agar. The infant's vaccination card shows incomplete immunization (only one dose of pentavalent vaccine received at 6 weeks). What is the most likely organism and the key virulence factor responsible for invasive disease?

Explanation

## Diagnosis: Haemophilus influenzae Type b Pneumonia ### Clinical Presentation The case describes: - Age 6 months (peak incidence of invasive Hib: 6 months–5 years) - Community-acquired pneumonia (fever, cough, tachypnea, focal consolidation) - Incomplete vaccination (only 1 of 3 primary doses of Hib-containing pentavalent vaccine) - Positive blood culture (indicates invasive bacteremia, not just respiratory colonization) ### Microbiological Identification | Feature | Finding | Significance | |---------|---------|---------------| | Gram stain | Gram-negative coccobacillus | Characteristic morphology | | Growth requirement | X and V factors | **Diagnostic for *Haemophilus*** | | Culture medium | Chocolate agar | Provides hemin (X) and NAD (V) | | Serotype | Type b (inferred from invasive disease + age + incomplete vaccination) | Most virulent serotype | **High-Yield:** *Haemophilus influenzae* is the only gram-negative coccobacillus that requires **both X (hemin) and V (NAD) factors** for growth. This is a key identification criterion. ### The Polyribosyl Phosphate (PRP) Capsule: The Critical Virulence Factor **Key Point:** The type b capsule is composed of polyribosyl phosphate (PRP), a polymer of ribose and phosphate. This capsule is the single most important virulence determinant for invasive Hib disease. ### Mechanism of Virulence ```mermaid flowchart TD A[PRP Capsule]:::outcome --> B[Inhibits complement fixation]:::action A --> C[Evades phagocytosis]:::action A --> D[Resists opsonization]:::action B --> E[Allows bacteremia]:::outcome C --> E D --> E E --> F[Invasion of CNS, joints, epiglottis]:::urgent G[Hib Vaccine<br/>PRP-protein conjugate]:::action --> H[Induces anti-PRP antibodies]:::outcome H --> I[Opsonization & complement activation]:::action I --> J[Prevention of invasive disease]:::outcome ``` **Clinical Pearl:** Non-typeable *H. influenzae* (NTHi) lacks the PRP capsule and is primarily a mucosal pathogen causing otitis media, sinusitis, and non-invasive respiratory tract infections. It rarely causes bacteremia or meningitis in immunocompetent hosts. ### Why Type b Causes Invasive Disease 1. **Capsular antigen mimics host polysaccharides** → poor immunogenicity in young children (T-cell-independent antigen) 2. **Evades complement-mediated killing** → survives in blood 3. **Resists opsonophagocytosis** → crosses blood–brain barrier and invades joints 4. **Incomplete vaccination** → insufficient anti-PRP antibodies to provide protection **Mnemonic: PRP = Protection Requires Priming** — Hib vaccine (PRP-protein conjugate) converts the T-cell-independent PRP antigen into a T-cell-dependent response, enabling memory B-cell formation and long-term protection. ### Hib Vaccine Mechanism The pentavalent vaccine (DPT + Hib + HepB) includes a **PRP-protein conjugate** (e.g., PRP-TT, PRP-OMP). Conjugation to a protein carrier (tetanus toxoid or meningococcal outer membrane protein) converts the polysaccharide into a T-cell-dependent antigen, inducing robust IgG responses and immunological memory. ### Clinical Manifestations of Invasive Hib - Meningitis (most common invasive form) - Epiglottitis ("cherry-red" epiglottis, stridor, airway emergency) - Bacteremia with focal infections (pneumonia, arthritis, osteomyelitis) - Sepsis and shock ### Management - **Empiric therapy:** Ceftriaxone or cefotaxime (β-lactamase-resistant) - **Dexamethasone:** For meningitis (reduces sequelae) - **Vaccination:** Complete Hib immunization series after recovery [cite:Harrison 21e Ch 297; Park 26e Ch 3]